Genetic polymorphisms in RNA binding proteins contribute to breast cancer survival

International Journal of Cancer

Volumn 132, Issue 3, 2013, Pages

  Upadhyay, Rohit ^a   Sanduja, Sandhya ^a   Kaza, Vimala ^a   Dixon, Dan A ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

breast cancer; HuR; polymorphism; RNA binding protein; TTP

Indexed keywords

ADENINE; GUANINE; MESSENGER RNA; RNA BINDING PROTEIN;

AFRICAN AMERICAN; ALLELE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CAUCASIAN; GENE EXPRESSION; GENE TARGETING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOTE; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA BINDING; RNA STABILITY; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

AFRICAN AMERICANS; ANTIGENS, SURFACE; BREAST NEOPLASMS; CYCLOOXYGENASE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC VARIATION; GENOTYPE; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; KAPLAN-MEIER ESTIMATE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; RNA, MESSENGER; RNA-BINDING PROTEINS; TRISTETRAPROLIN;

EID: 84870190401     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27789     Document Type: Article

References (48)

1. Siegel R, Ward E, Brawley O, et al,. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-36.
2. Lichtenstein P, Holm NV, Verkasalo PK, et al,. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85.
3. Turnbull C, Ahmed S, Morrison J, et al,. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 2010; 42: 504-7.
4. Adams SA, Smith ER, Hardin J, et al,. Racial differences in follow-up of abnormal mammography findings among economically disadvantaged women. Cancer 2009; 115: 5788-97.
5. Smith ER, Adams SA, Das IP, et al,. Breast cancer survival among economically disadvantaged women: the influences of delayed diagnosis and treatment on mortality. Cancer Epidemiol Biomarkers Prev 2008; 17: 2882-90.
6. Cunningham JE, Montero AJ, Garrett-Mayer E, et al,. Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes Control 2010; 21: 399-409.
7. Garneau NL, Wilusz J, Wilusz CJ,. The highways and byways of mRNA decay. Nat Rev Mol Cell Biol 2007; 8: 113-26.
8. Lopez de Silanes I, Quesada MP, Esteller M,. Aberrant regulation of messenger RNA 3'-untranslated region in human cancer. Cell Oncol 2007; 29: 1-17.
9. Gruber AR, Fallmann J, Kratochvill F, et al,. AREsite: a database for the comprehensive investigation of AU-rich elements. Nucleic Acids Res 2010; 39: D66-9.
10. Bakheet T, Williams BR, Khabar KS,. ARED 3.0: the large and diverse AU-rich transcriptome. Nucleic Acids Res 2006; 34: D111-14.
11. Lai WS, Carballo E, Thorn JM, et al,. Interactions of CCCH zinc finger proteins with mRNA. Binding of tristetraprolin-related zinc finger proteins to AU-rich elements and destabilization of mRNA. J Biol Chem 2000; 275: 17827-37.
12. Sanduja S, Blanco FF, Dixon DA,. The roles of TTP and BRF proteins in regulated mRNA decay. Wiley Interdiscip Rev RNA 2010; 2: 42-57.
13. Abdelmohsen K, Gorospe M,. Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA 2010; 1: 214-29.
14. Fan XC, Steitz JA,. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J 1998; 17: 3448-60.
15. Brennan CM, Steitz JA,. HuR and mRNA stability. Cell Mol Life Sci 2001; 58: 266-77.
16. Gubin MM, Calaluce R, Davis JW, et al,. Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis. Cell Cycle 2010; 9: 3337-46.
17. Denkert C, Weichert W, Winzer KJ, et al,. Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res 2004; 10: 5580-6.
18. Saunus JM, French JD, Edwards SL, et al,. Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR. Cancer Res 2008; 68: 9469-78.
19. Pryzbylkowski P, Obajimi O, Keen JC,. Trichostatin A and 5 Aza-2' deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR. Breast Cancer Res Treat 2008; 111: 15-25.
20. Guo X, Hartley RS,. HuR Contributes to cyclin E1 deregulation in MCF-7 breast cancer cells. Cancer Res 2006; 66: 7948-56.
21. Yuan Z, Sanders AJ, Ye L, et al,. Knockdown of human antigen R reduces the growth and invasion of breast cancer cells in vitro and affects expression of cyclin D1 and MMP-9. Oncol Rep 2011; 26: 237-45.
22. Suswam EA, Nabors LB, Huang Y, et al,. IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3' untranslated region: involvement of divergent RNA-binding factors HuR, KSRP and TIAR. Int J Cancer 2005; 113: 911-19.
23. Carballo E, Lai WS, Blackshear PJ,. Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood 2000; 95: 1891-9.
24. Lai WS, Carballo E, Strum JR, et al,. Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol Cell Biol 1999; 19: 4311-23.
25. Young LE, Sanduja S, Bemis-Standoli K, et al,. The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology 2009; 136: 1669-79.
26. Suswam E, Li Y, Zhang X, et al,. Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells. Cancer Res 2008; 68: 674-82.
27. Marderosian M, Sharma A, Funk AP, et al,. Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling. Oncogene 2006; 25: 6277-90.
28. Stoecklin G, Gross B, Ming XF, et al,. A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA. Oncogene 2003; 22: 3554-61.
29. Brennan SE, Kuwano Y, Alkharouf N, et al,. The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis. Cancer Res 2009; 69: 5168-76.
30. Patil CS, Liu M, Zhao W, et al,. Targeting mRNA stability arrests inflammatory bone loss. Mol Ther 2008; 16: 1657-64.
31. Stoecklin G, Tenenbaum SA, Mayo T, et al,. Genome-wide analysis identifies interleukin-10 mRNA as target of tristetraprolin. J Biol Chem 2008; 283: 11689-99.
32. Jalonen U, Nieminen R, Vuolteenaho K, et al,. Down-regulation of tristetraprolin expression results in enhanced IL-12 and MIP-2 production and reduced MIP-3alpha synthesis in activated macrophages. Mediat Inflamm 2006; 2006: 40691.
33. Qian X, Ning H, Zhang J, et al,. Posttranscriptional regulation of IL-23 expression by IFN-gamma through tristetraprolin. J Immunol 2011; 186: 6454-64.
34. Al-Souhibani N, Al-Ahmadi W, Hesketh JE, et al,. The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes. Oncogene 2010; 29: 4205-15.
35. Suzuki T, Tsutsumi A, Suzuki H, et al,. Tristetraprolin (TTP) gene polymorphisms in patients with rheumatoid arthritis and healthy individuals. Mod Rheumatol 2008; 18: 472-9.
36. Xu Z, Taylor JA,. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 2009; 37: W600-5.
37. Howe LR,. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 2007; 9: 210-18.
38. Liu CH, Chang SH, Narko K, et al,. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276: 18563-9.
39. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM,. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3'-untranslated region. J Biol Chem 2000; 275: 11750-7.
40. Turaga K, Acs G, Laronga C,. Gene expression profiling in breast cancer. Cancer Control 2010; 17: 177-82.
41. Shavers VL, Harlan LC, Stevens JL,. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer 2003; 97: 134-47.
42. Ademuyiwa FO, Olopade OI,. Racial differences in genetic factors associated with breast cancer. Cancer Metastasis Rev 2003; 22: 47-53.
43. Jones BA, Kasl SV, Howe CL, et al,. African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 2004; 101: 1293-301.
44. Lantz PM, Mujahid M, Schwartz K, et al,. The influence of race, ethnicity, and individual socioeconomic factors on breast cancer stage at diagnosis. Am J Public Health 2006; 96: 2173-8.
45. Carrick DM, Chulada P, Donn R, et al,. Genetic variations in ZFP36 and their possible relationship to autoimmune diseases. J Autoimmun 2006; 26: 182-96.
46. Joseph SB, Castrillo A, Laffitte BA, et al,. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003; 9: 213-19.
47. Griseri P, Bourcier C, Hieblot C, et al,. A synonymous polymorphism of the tristetraprolin (TTP) gene, an AU-rich mRNA-binding protein, affects translation efficiency and response to herceptin treatment in breast cancer patients. Hum Mol Genet 2011; 20: 4556-68.
48. Gebeshuber CA, Zatloukal K, Martinez J,. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 2009; 10: 400-5.